ANTI-THYMOCYTE GLOBULIN TREATMENT IN PATIENTS WITH APLASTIC-ANEMIA - A PROSPECTIVE RANDOMIZED TRIAL
ANTI-THYMOCYTE GLOBULIN TREATMENT IN PATIENTS WITH APLASTIC-ANEMIA - A PROSPECTIVE RANDOMIZED TRIAL
复制标题
DOI：
10.1056/nejm198301203080301
复制
发表时间：
1983-01-01
影响因子：
158.5
通讯作者：
GALE, RP
中科院分区：
文献类型：
--
作者：
CHAMPLIN, R;HO, W;GALE, RP
采用随机对照研究方法，观察抗胸腺细胞球蛋白治疗中重度再生障碍性贫血的疗效。在21名最初随机接受抗胸腺细胞球蛋白（连续8天静脉注射）的患者中，11名患者在3个月内造血功能持续改善。21例仅接受支持治疗的对照组患者无一改善（P = 0.0005）。随后接受抗胸腺细胞球蛋白治疗的12名对照患者中有6名改善。应答者的造血功能逐渐改善，但没有一个完全恢复正常的外周血细胞计数。骨髓衰竭的严重程度、年龄、再生障碍性贫血的病因和输血史对治疗结果没有明显影响。从诊断到抗胸腺细胞球蛋白治疗的时间间隔与治疗反应的机会呈负相关，尽管这种相关性没有统计学意义。抗胸腺细胞球蛋白对部分再生障碍性贫血患者的造血功能有明显的改善作用。
The efficacy of antithymocyte globulin for the treatment of moderate to severe aplastic anemia was studied in a randomized controlled study. Of 21 patients initially randomized to receive antithymocyte globulin (given i.v. of 8 consecutive days), 11 had sustained improvement in hematopoiesis within 3 mo. of treatment; none of 21 control patients who received supportive care alone improved (P = 0.0005). Six of 12 control patients who subsequently received antithymocyte globulin improved. Responders had gradual improvement in hematopoiesis, but none recovered completely normal peripheral-blood counts. The severity of bone-marrow failure, age, cause of aplastic anemia, and transfusion history had no apparent bearing on treatment outcome. The interval from diagnosis to antithymocyte globulin treatment correlated inversely with the chance of a treatment response, although this correlation was not statistically significant. Evidently, antithymocyte globulin is effective in improving hematopoiesis in some patients with aplastic anemia.